Lab Brief - November 2024

Good sense in the UK – and some of the same in the EU

Hello again,

According to Invest 2035, which sets out how government intends to deliver growth: ‘Over the next decade, the life sciences sector holds enormous potential to drive economic growth and productivity. It is built on over 6,800 businesses that generated over £100 billion in turnover(2021 to 2022 figures). The UK is also home to 4 of the top 10 global universities for life sciences and medicine, and with the expertise of the NHS, the UK is a global hub for innovation’.

So that’s all good, but threats to UK success in life sciences have come in the shape of the European Parliament's rapid revision of the MDR/IVDR regulations requiring the re-certification of tens if not hundreds of thousands of products.

A recent German-inspired resolution from the European Parliament has called on the EU Commission to act by the end of the first quarter of 2025 to relieve the burden on medical technology companies which have suffered from the bureaucratic and lengthy certification processes. 

The resolution demands:

  • The simplification and acceleration of certification procedures and the introduction of transparent and binding deadlines.
  • The elimination of unnecessary recertifications and the reduction of administrative burdens, especially for SMEs.
  • The creation of fast-track procedures for innovative products and products that address undermet medical needs.
  • The full implementation of the European product database EUDAMED to create more transparency.
  • Clear regulations for medical devices for rare diseases and increased support for SMEs, for example through guidelines and model forms.

Meanwhile, in the UK a consultation is underway to introduce ‘International reliance’ a mechanism through which some medical devices could access the GB market more quickly if they have already been approved by a comparable regulator in another country which seems a sensible step to avoiding doubling the compliance costs of UK manufacturers. It is also looking at keeping some EU law in force to help smooth out some of the bumps.

Thank goodness – some sense at last!

Toodle pip!

Jacqueline

 

In this month's issue:

 

 

Say hello to your Lab Board Members

 

 

 

New venue for GAMBICA conference on future of lab research

 

 

Prognosis poor for French lab sales – China also an issue…

 

 

 

Company news: New joiner brings the graphene revolution to GAMBICA

 

 

Your invitation to brief the North Western Universities Purchasing Consortium

 

 

 

 

 

Lab staff exposed to biological risk says HSE – Plus further moves to minimise animal testing

 

 

 

HR News: Could salary sacrifice mitigate the National Insurance Contributions hike?

 

 

 

Lab construction updates: London, Hull and Cambridge

 

 

 

Export news: Footfall criticised at Medica… FedEx bans mixed packages of electrical equipment and liquids… Virtual trade mission to Uruguay and Panama… UK genomics spotlight launched by DBT…

 

Also inside: Your feedback sought on trade strategy, medical devices and planning of biotech labsGAMBICA events… industry events… and your questions & answers is back!